Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that the glassy layer of hair follicles in guinea pigs consists of thick collagen-type fibrils organized into two distinct arrays, whereas in young mice, the fibrils are thinner and develop between the outer root sheath and fibroblasts.

This study found that non-ablative fractional erbium glass laser treatment affected gene regulation in human skin models by downregulating MMP and interleukin expression, suggesting potential roles in dermal remodeling and anti-inflammatory effects.

In this study, collagen type I, skin fibroblasts, and macrophages did not show remarkable changes in androgenic alopecia patients' scalp tissues after treatment with 1550 nm fractional Er:Glass laser, despite improved hair regrowth.

This study found that 1,550-nm Er:Glass fractional laser treatment increased hair density and shaft diameter in patients with androgenetic alopecia, but did not up-regulate Wnt10A and IGF-1 mRNA expression.

This study found that 1550-nm Er:Glass fractional laser treatment significantly increased hair density and shaft diameter in patients with androgenetic alopecia, though the mechanism may not involve Wnt10A or IGF-1 expression.

Laser treatment shows promise for hair growth, but needs further research.

This study found that treatment with a 1550 nm fractional erbium–glass laser increased hair density and thickness in women with female pattern hair loss, suggesting it may be an effective and safe option.

This study found that combining fractional erbium-glass laser therapy with topical minoxidil significantly improved hair density and diameter in men with androgenetic alopecia compared to using minoxidil alone over a 24-week period, with no serious adverse events reported.

In this study, patients with androgenic alopecia who underwent 10 sessions of 1540-nm fractional erbium glass laser treatment over 5 months experienced significant improvements in hair density and thickness, with no major safety concerns reported.

The 1540nm fractional erbium-glass laser helps treat hair loss caused by hormones.

This study reported that combining Erbium Glass 1550nm laser therapy with scalp injections of minoxidil, finasteride, growth factors, and vitamins was an effective and safe treatment for androgenetic alopecia, with 96.77% of participants expressing satisfaction, especially those who underwent more than six sessions.

This study found that 1,540 nm fractional erbium-glass laser treatment combined with topical minoxidil significantly increased hair regrowth in alopecia areata patches compared to minoxidil alone, with response rates of 60% versus 16%, though the long-term effects remain unknown.

This article reviews the characteristics and distribution of alopecia areata and reports no new clinical results.

This systematic review suggests that laser treatments, especially low-level laser therapy and excimer lasers, may be effective for hair regrowth, though further large-scale studies are needed for validation.

Fractionated laser therapy, especially erbium-glass laser, effectively increases hair thickness in people with hair loss but doesn't increase the number of hairs.

This study observed that both PRP and 1550 nm fractional erbium-glass laser improved AGA, with greater hair density in patients receiving the combination therapy and no side effects reported.

This review discusses the potential of three-dimensional printed mesoporous scaffolds for drug delivery applications, particularly for bone cells and tissues, but reports no new clinical results.

This study compared the microscopic treatment zones created by different fractional lasers and radiofrequency in swine skin, finding distinct patterns and damage levels for each technology.

This study reviews the use of lasers and light therapies as treatment options for managing the two most common types of alopecia—androegenetic alopecia and alopecia areata—highlighting that existing FDA-approved drugs like minoxidil and finasteride are partially effective, necessitating additional therapeutic approaches.

This literature review reported that fractional lasers, like the 1550-nm nonablative erbium-glass laser, may enhance hair regrowth by stimulating a wound healing process, but more randomized controlled trials are needed to confirm their effectiveness and optimize treatment parameters.

This study found that both fractional and excimer lasers are effective in increasing hair density and promoting regrowth in various types of alopecia, although further trials are needed to compare their efficacy to more traditional treatments.

In this study, researchers reported that IL-17C plays a key pro-inflammatory role in human skin diseases and may be a promising therapeutic target for inflammatory skin conditions.

This study found that DC-HIL+ myeloid derived suppressor cells are increased in the blood and skin of patients with cutaneous lupus erythematosus and show immunosuppressive properties.

This review discusses various light and laser treatments for hair loss, highlighting potential benefits but emphasizes the need for more scientific evidence before recommendations can be made.

This study suggests that a 1,550-nm fractional erbium-glass laser may stimulate hair growth in both an alopecia mouse model and human subjects with male pattern hair loss, though further research is needed to determine its clinical applications.

This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.

This systematic review found that light and laser therapies, including excimer and erbium-glass lasers, generally increase hair density and diameter in various types of alopecia, with particularly notable effects in androgenic alopecia but limited efficacy in telogen effluvium.

This study observed hair regrowth and increased density in four cases of androgenetic alopecia treated with a non-ablative erbium glass fractional laser and topical finasteride, with no significant side effects reported.

This study found that bioactive glass-based camouflage composite particles enhanced the coagulation effects in bleeding models by forming a fibrin network and activating coagulation pathways, suggesting potential use as an emergency hemostasis biomaterial.

In this study, both erbium: YAG and erbium: glass lasers were found to be effective in treating androgenetic alopecia by improving hair density, growth rate, and thickness, particularly when combined with other therapies like minoxidil or platelet-rich plasma, though individual patient responses varied.